Direct-to-consumer Genetic DNA Tests Market Size and ForecastThe Direct-to-consumer (DTC) genetic DNA testing market has ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

According to Benzinga Pro, GSK's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers. Did you know that ...

GSK plc (NYSE:GSK) is engaged in research, development, and production of vaccines, as well as specialized and general medicines aimed at preventing and treating various diseases. In early March, ...

This action was surfaced by Law.com Radar, which delivers real-time alerting on new litigation across more than 2,600 state and federal courts. Click here to get started and be first to act on ...

Ovintiv trades at an EV/EBITDA multiple of 3.97x and offers an attractive free cash flow yield of 11%. InvestingPro analysis indicates the stock is currently undervalued, suggesting potential for ...

Want deeper insights into PTON’s financial health and growth prospects? Access comprehensive analysis and more ProTips through InvestingPro. To address growth challenges, Peloton has been actively ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Learn More. Just over a year ago, I ran the rule over GSK (LSE: GSK) shares. They looked very cheap and were offering a growing dividend. However, I chose instead to invest in FTSE 100 ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.